Immunohistochemical analysis of desmoid tumours

Journal of Clinical Pathology

Volumn 58, Issue 11, 2005, Pages 1152-1156

  Leithner, A ^a   Gapp, M ^a   Radl, R ^a   Pascher, A ^a   Krippl, P ^a   Leithner, K ^a   Windhager, R ^a   Beham, A ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTIESTROGEN; CATHEPSIN D; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; IMATINIB; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; SOMATOSTATIN; STEM CELL FACTOR;

ADJUVANT THERAPY; ARTICLE; DESMOID TUMOR; DRUG EFFECT; FIBROMATOSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL;

ABDOMINAL NEOPLASMS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CATHEPSIN D; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; FEMALE; FIBROMATOSIS, AGGRESSIVE; HUMANS; INFANT; INFANT, NEWBORN; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SOFT TISSUE NEOPLASMS; SOMATOSTATIN; TUMOR MARKERS, BIOLOGICAL;

EID: 27644540127     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2005.026278     Document Type: Article

References (37)

1. Goldblum J, Fletcher JA. Desmoid type fibromatoses. In: Fletcher CDM, Unni KK, Mertens F, eds. World Health Organisation classification of tumours. Pathology and genetics of tumours of soft tissue and bone. Lyon: IARC, 2002:83-4.
2. Reitamo JJ, Scheinin TM, Hayry P. The desmoid syndrome. New aspects in the cause, pathogenesis and treatment of the desmoid tumor. Am J Surg 1986;151:230-7.
3. Leithner A, Gapp M, Leithner K, et al. Margins in extra-abdominal desmoid tumors: a comparative analysis. J Surg Oncol 2004;86:152-6.
4. Hansmann A, Adolph C, Vogel T, et al. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer 2004;100:612-20.
5. Easter DW, Halasz NA. Recent trends in the management of desmoid tumors. Summary of 19 cases and review of the literature. Ann Surg 1989;210:765-9.
6. Pignatti G, Barbanti-Brodano G, Ferrari D, et al. Extraabdominal desmoid tumor. A study of 83 cases. Clin Orthop 2000;375:207-13.
7. Lim CL, Walker MJ, Mehta RR, et al. Estrogen and antiestrogen binding sites in desmoid tumors. Eur J Cancer Clin Oncol 1986;22:583-7.
8. Alman BA, Goldberg MJ, Naber SP, et al. Aggressive fibromatosis. J Pediatr Orthop 1992;12:1-10.
9. Hayry P, Reitamo JJ, Vihko R, et al. The desmoid tumor. III. A biochemical and genetic analysis. Am J Clin Pathol 1982;77:681-5.
10. Maddalozzo J, Tenta LT, Hutchinson LR, et al. Juvenile fibromatosis: hormonal receptors. Int J Pediatr Otorhinolaryngol 1993;25:191-9.
11. Reis-Filho JS, Milanezi F, Pope LZ, et al. Primary fibromatosis of the breast in a patient with multiple desmoid tumors-report of a case with evaluation of estrogen and progesterone receptors. Pathol Res Pract 2001;197:775-9.
12. Weiss SW, Langloss JM, Shmookler BM, et al. Estrogen receptor protein in bone and soft tissue tumors. Lab Invest 1986;54:689-94.
13. McDougall A, McGarrity G. Extra-abdominal desmoid tumours. J Bone Joint Surg Br 1979;61-B:373-7.
14. Sorensen A, Keller J, Nielsen OS, et al. Treatment of aggressive fibromatosis: a retrospective study of 72 patients followed for 1-27 years. Acta Orthop Scand 2002;73:213-19.
15. Serpell JW, Tang HS, Donnovan M. Factors predicting local recurrence of desmoid tumours including proliferating cell nuclear antigen. Aust N Z J Surg 1999;69:782-9.
16. Arai N, Mitomi H, Uesugi H, et al. An aggressive desmoid tumor in a patient with familial adenomatous polyposis: immunohistochemical findings. Am J Gastroenterol 1999;94:530-2.
17. Fong Y, Rosen PP, Brennan MF. Multifocal desmoids. Surgery 1993;114:902-6.
18. Chaudhuri PK, Walker MJ, Beattie CW, et al. Presence of steroid receptors in human soft tissue sarcomas of diverse histological origin. Cancer Res 1980;40:861-5.
19. Bulow S. Sulindac and tamoxifen in the treatment of desmoid tumours in patients with familial adenomatous polyposis. Colorectal Dis 2001;3:266-7.
20. Heidemann J, Ogawa H, Otterson MF, et al. Antiangiogenic treatment of mesenteric desmoid tumors with toremifene and interreron alfa-2b: report of two cases. Dis Colon Rectum 2004;47:118-22.
21. Chaudhuri PK, Walker MJ, Beattie CW, et al. Distribution of steroid hormone receptors in human soft tissue sarcomas. Surgery 1981;90:149-53.
22. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:1-15.
23. Skliris GP, Parkes AT, Limer JL, et al. Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue. J Pathol 2002;197:155-62.
24. Biermann JS. Desmoid tumors. Curr Treat Options Oncol 2000;1:262-6.
25. De Pas T, Bodei L, Pelosi G, et al. Peptide receptor radiotherapy: a new option for the management of aggressive fibromatosis on behalf or tne Italian sarcoma group. Br J Cancer 2003;88:645-7.
26. Morris CD, Gorlick R, Huvos G, et al. Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma. Clin Orthop Relat Res 2001;382:59-65.
27. Kouho H, Aoki T, Hisaoka M, et al. Clinicopathological and interphase cytogenetic analysis of desmoid tumours. Histopathology 1997;31:336-41.
28. Hoos A, Lewis JJ, Antonescu CR, et al. Characterization of molecular abnormalities in human fibroblastic neoplasms: a model for genotype-phenotype association in soft tissue tumors. Cancer Res 2001;61:3171-5.
29. Brueckl WM, Preuss JM, Wein A, et al. Ki-67 expression and residual tumour (R) classification are associated with disease-free survival in desmoid tumour patients. Anticancer Res 2001;21:3615-20.
30. Heinrich MC, Blanke CD, Druker BJ, et al. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002;20:1692-703.
31. Mace J, Sybil BJ, Sondak V, et al. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer 2002;95:2373-9.
32. Yantiss RK, Spiro IJ, Compton CC, et al. Gastrointestinal stromal tumor versus intra-abdominal fibromatosis of the bowel wall: a clinically important differential diagnosis. Am J Surg Pathol 2000;24:947-57.
33. Lucas DR, al Abbadi M, Tabaczka P, et al. c-Kit expression in desmoid fibromatosis. Comparative immunohistochemical evaluation of two commercial antibodies. Am J Clin Pathol 2003;119:339-45.
34. Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol 2000;13:1134-42.
35. Yamaguchi U, Hasegawa T, Masuda T, et al. Differential diagnosis of gastrointestinal stromal tumor and other spindle cell tumors in the gastrointestinal tract based on immunohistochemical analysis. Virchows Arch 2004;445:142-50.
36. Hornick JL, Fletcher CD. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol 2002;117:188-93.
37. Miettinen M. Are desmoid tumors kit positive? Am J Surg Pathol 2001;25:549-50.